Key Ideas

A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial. Mutations in RAS are present in more than 90 percent of pancreatic cancer cases, but until recently this protein has long been considered undruggable. Regulatory submission for daraxonrasib is currently underway, with a number of trials now testing this drug earlier in the treatment course of this disease.

Targeting the Undruggable: Why RAS Inhibition Changes the Conversation

Pancreatic ductal adenocarcinoma remains one of the most difficult cancers to treat; frontline chemotherapy regimens such as FOLFIRINOX, NALIRINOX, and gemcitabine plus nab-paclitaxel typically produce a median survival under one year. RAS mutations, present in roughly 85 to 95 percent of patients (most commonly KRAS G12D, followed by G12V and G12R), are central to the disease's biology: the mutated protein stays locked in its active, GTP-bound state, continuously driving tumor cell growth and survival. For decades, RAS was considered essentially undruggable. Its surface is unusually smooth, offering few pockets for small-molecule binding, and it binds its nucleotide partners with extremely high affinity, leaving little room for a competing drug to intervene.

The past decade changed that picture. Improved understanding of RAS biology enabled the first generation of mutation-specific inhibitors targeting KRAS G12C, a variant far more common in lung and colorectal cancer than in pancreatic cancer. In the small subset of pancreatic cancer patients with this mutation, those early inhibitors produced response rates in the 20 to 30 percent range, but relevance was limited by how rare G12C is in this disease.

RASolute 302: A Multi-Selective RAS Inhibitor Nearly Doubles Survival

Daraxonrasib works differently. It binds a chaperone protein, cyclophilin A, forming a complex that then binds mutant RAS to create a non-covalent inhibitory tri-complex, blocking RAS from signaling through its downstream effectors, RAF and MEK. Because this mechanism does not depend on a specific mutation-created binding pocket, daraxonrasib is active across multiple RAS variants, and even shows efficacy in RAS wild-type pancreatic cancer.  

Early phase 1/2 data, first presented in 2023 and later published in the New England Journal of Medicine, showed encouraging activity in the second-line setting: an objective response rate around 35 percent and median progression-free and overall survival in the 13-to-14-month range, well beyond what chemotherapy typically achieves in this context. However, promising data in early-phase trials in pancreatic cancer frequently fail to hold up in subsequent larger randomized trials, so confirmation in a phase 3 study was essential.

That confirmation came from RASolute 302, a global, randomized trial of roughly 500 patients with previously treated metastatic pancreatic cancer, open to patients regardless of RAS mutation status. Patients were randomized to daraxonrasib 300 mg once daily vs. investigator's choice of standard chemotherapy. The results, presented at the 2026 plenary session of the American Society of Clinical Oncology (ASCO) Annual meeting and simultaneously published in the New England Journal of Medicine, were striking: in the primary analysis population with codon 12 mutations, daraxonrasib nearly doubled median overall survival compared with chemotherapy, with a hazard ratio for death of 0.40, a level of benefit rarely seen in pancreatic cancer trials, where a hazard ratio of 0.6 to 0.7 has historically been considered a good result. Progression-free survival showed a similarly strong hazard ratio of 0.45. Roughly a third of patients achieved an objective response, and quality-of-life measures favored daraxonrasib as well. Benefit did not appear limited to patients with RAS mutations: the minority of patients with RAS wild-type tumors, who may remain RAS-pathway dependent through other mechanisms, also appeared to derive benefit, though this subgroup was small.

Managing the Signature Side Effect

Daraxonrasib's most distinctive toxicity is a rash affecting the face and trunk, occurring in close to 90 percent of patients. A fairly standardized preemptive regimen, including broad-spectrum sunscreen, topical steroid cream for the face and chest, and oral antibiotics, is recommended for all patients. Severe symptoms may require dose interruption or reduction from 300 mg to 200 mg daily, but most patients are ultimately able to remain on treatment with appropriate supportive care. As this drug moves into broader community use, oncology practices will need a learning curve around proactive dermatologic management, particularly given how variable access to dermatology consultation can be depending on geography.

What Comes Next: Earlier Lines and Resistance

Two ongoing trials point toward where this drug is heading next. RASolute 303 is testing daraxonrasib in the frontline setting across three arms: chemotherapy alone, chemotherapy plus daraxonrasib, or daraxonrasib alone as a chemotherapy-free option, a possibility that would have seemed far-fetched even a decade ago for patients with a new diagnosis of metastatic pancreatic cancer. RASolute 304 is testing this drug for patients with earlier-stage disease who have already undergone surgery and completed their pre- and/or post-operative chemotherapy, to see if it may help reduce the likelihood of relapse.  Additionally, a growing pipeline of more selective RAS inhibitors, targeting specific alleles such as G12D, is also advancing, with early data suggesting further gains may be possible for molecularly defined subsets of patients.

Resistance remains the central long-term challenge. As with most targeted therapies, patients on daraxonrasib eventually show evidence of disease progression, through both acquired mutations as well non-genetic mechanisms such as epithelial-to-mesenchymal transition. Chemotherapy will likely remain part of the treatment sequence for many patients even as RAS-targeted options expand, and defining the best approach after RAS-inhibitor resistance is an important area for ongoing research.

For Patients

If you or a loved one has metastatic pancreatic cancer, a new type of oral medication called a RAS(ON) inhibitor, daraxonrasib, has shown a substantial survival benefit compared with standard chemotherapy in patients whose cancer has already progressed on prior chemotherapy. In a large clinical trial, patients taking this once-daily pill lived nearly twice as long on average as those receiving chemotherapy, with generally better quality of life.

This medication is not yet FDA approved, though an Expanded Access Program has allowed some patients to receive it before it becomes commercially available. The most common side effect is a facial and chest rash that, while common, can typically be prevented or managed with sunscreen, topical steroids, and an oral antibiotic, allowing most patients to remain on treatment.

Ask your oncologist whether this medication, or a clinical trial involving it, may be appropriate for your specific situation, including timing relative to your current treatment.

Key Takeaways

  • RAS mutations, most commonly KRAS G12D, drive an estimated 85 to 95 percent of pancreatic ductal adenocarcinoma cases, a target long considered undruggable due to RAS's smooth protein structure and high-affinity nucleotide binding.

  • The Phase 3 RASolute 302 trial found that daraxonrasib, an oral multi-selective RAS(ON) inhibitor, nearly doubled median overall survival compared with chemotherapy in previously treated metastatic pancreatic cancer, with a hazard ratio for death of 0.40.

  • A rash affecting the face and trunk occurs in roughly 90 percent of patients but is generally manageable with a standardized preventive regimen, allowing most patients to remain on treatment.

  • Ongoing trials, including RASolute 303, are testing daraxonrasib in the frontline setting, including as a chemotherapy-free option, and additional allele-specific RAS inhibitors are advancing in early clinical development.

  • Resistance to RAS-targeted therapy remains an important area of ongoing investigation, and chemotherapy is likely to remain part of the treatment sequence for many patients.

References

  1. O'Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. New England Journal of Medicine. Published online May 31, 2026.

  2. Wolpin BM, Wainberg ZA, Hendifar A, et al. Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma: primary and final analysis from the phase 3 RASolute 302 study. Presented at the 2026 ASCO Annual Meeting; Abstract LBA5.

  3. Phase 1/2 study of daraxonrasib (RMC-6236) in previously treated metastatic pancreatic ductal adenocarcinoma. New England Journal of Medicine, 2023 (ESMO presentation), with updated results.

  4. Revolution Medicines. Daraxonrasib demonstrates unprecedented overall survival benefit in pivotal Phase 3 RASolute 302 clinical trial in patients with metastatic pancreatic cancer. Press release, April 13, 2026.

  5. Phase 3 study of daraxonrasib (RMC-6236) with or without chemotherapy as first-line treatment for metastatic pancreatic adenocarcinoma (RASolute 303). ClinicalTrials.gov.